Financial Contrast: FULGENT GENETIC (FLGT) versus Its Competitors

FULGENT GENETIC (NASDAQ: FLGT) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare FULGENT GENETIC to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of current ratings for FULGENT GENETIC and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
FULGENT GENETIC 0 0 3 0 3.00
FULGENT GENETIC Competitors 251 1812 3247 105 2.59

FULGENT GENETIC currently has a consensus price target of $10.67, suggesting a potential upside of 133.41%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.73%. Given FULGENT GENETIC’s stronger consensus rating and higher probable upside, analysts plainly believe FULGENT GENETIC is more favorable than its peers.

Valuation and Earnings

This table compares FULGENT GENETIC and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
FULGENT GENETIC $20.81 million $2.17 million -12.03
FULGENT GENETIC Competitors $2.02 billion $430.74 million -70.96

FULGENT GENETIC’s peers have higher revenue and earnings than FULGENT GENETIC. FULGENT GENETIC is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares FULGENT GENETIC and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
FULGENT GENETIC -0.42% -0.02% -0.02%
FULGENT GENETIC Competitors -327.91% -35.29% -12.43%

Insider & Institutional Ownership

16.8% of FULGENT GENETIC shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 17.2% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


FULGENT GENETIC beats its peers on 6 of the 11 factors compared.


Fulgent Genetics, Inc. is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company’s test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The Company’s gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.

Receive News & Ratings for FULGENT GENETIC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FULGENT GENETIC and related companies with's FREE daily email newsletter.

Leave a Reply